Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.81 |
| ▸ | CES2 | O00748 | 4/20 | 0.56 |
| ▸ | CES1 | P23141 | 4/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.54 |
| ▸ | PPARG | P37231 | 7/20 | 0.54 |
| ▸ | PPARD | Q03181 | 7/20 | 0.54 |
| ▸ | PPARA | Q07869 | 7/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 5/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | FABP4 | P15090 | 2/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL740728 | 1.00 | ALDH1A1 (0.81) | ALDH1A1CES2CES1GPR84PPARG | |
| SCHEMBL17061008 | 1.00 | ALDH1A1 (0.81) | ALDH1A1CES2CES1GPR84PPARG | |
| SCHEMBL168214 | 1.00 | ALDH1A1 (0.81) | ALDH1A1CES2CES1GPR84PPARG | |
| Hexadecanoic Acid Dimethylamide SCHEMBL148603 | 1.00 | ALDH1A1 (0.81) | ALDH1A1CES2CES1GPR84PPARG | |
| SCHEMBL2484949 | 1.00 | ALDH1A1 (0.81) | ALDH1A1CES2CES1GPR84PPARG | |
| SCHEMBL13714936 | 1.00 | ALDH1A1 (0.81) | ALDH1A1CES2CES1GPR84PPARG | |
| SCHEMBL168532 | 1.00 | ALDH1A1 (0.81) | ALDH1A1CES2CES1GPR84PPARG | |
| SCHEMBL8564464 | 1.00 | ALDH1A1 (0.81) | ALDH1A1CES2CES1GPR84PPARG | |
| SCHEMBL22406917 | 1.00 | ALDH1A1 (0.81) | ALDH1A1CES2CES1GPR84PPARG | |
| SCHEMBL5394356 | 1.00 | ALDH1A1 (0.81) | ALDH1A1CES2CES1GPR84PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114122440-B | Lithium/carbon fluoride or lithium/metal fluoride battery electrolyte | 厦门大学 | 2023-10-13 | — | — | CN | claimed |
| EP-4018266-A1 | METHOD FOR MAKING LITHOGRAPHIC PRINTING PLATES | Eastman Kodak Company (US) | 2022-06-29 | — | — | EP | claimed |
| CN-114122440-A | Lithium/carbon fluoride or lithium/metal fluoride battery electrolyte | 厦门大学 | 2022-03-01 | — | — | CN | claimed |
| US-20210221116-A1 | METHOD FOR MAKING LITHOGRAPHIC PRINTING PLATES | BANK OF AMERICA, N.A., AS AGENT | 2021-07-22 | — | — | US | claimed |
| US-5427795-A | Fungicide, herbicide, insecticides | BAYER AKTIENGESELLSCHAFT (DE) | 1995-06-27 | — | — | US | claimed |
| EP-0453899-B1 | Use of alkyl carboxylic acid dimethyl amides for inhibiting crystallisation | BAYER AG (DE) | 1993-12-29 | — | — | EP | claimed |
| US-5230892-A | Fungicides, herbicides or insecticides with additives or dispersants and carriers in solid formation | BAYER AKTIENGESELLSCHAFT (DE) | 1993-07-27 | — | — | US | claimed |
| US-5206225-A | ALKYLCARBOXYLIC ACID DIMETHYLAMIDES AS CRYSTALLIZATION INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 1993-04-27 | — | — | US | claimed |
| JP-4225901-A | — | — | None | — | — | JP | disclosed |
| WO-2026106260-A1 | NOVEL DIPHENYLETHER DERIVATIVE AND USE THEREOF | 광주과학기술원 | 2026-05-21 | — | — | WO | disclosed |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| CN-117561058-A | CDK2 inhibitors and methods of use thereof | 塞迪拉治疗股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20230302091-A1 | Combination Therapy with Controlled-Release CNP Agonists | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2023-09-28 | — | — | US | disclosed |
| US-20230302091-A1 | Combination Therapy with Controlled-Release CNP Agonists | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2023-09-28 | — | — | US | disclosed |
| JP-H04225901-A | USE OF ALKYLCARBOXYLIC ACID DIMETHYL AMIDE AS CRYSTALLIZATION INHIBITOR | BAYER AG | 1992-08-14 | — | — | JP | disclosed |
| US-5043466-A | Preparation of cyclohexanol derivatives and novel thioamide intermediates | JOHN WYETH & BRO., LIMITED (GB) | 1991-08-27 | — | — | US | disclosed |
| US-4954339-A | ANTICHOLESTEROL AGENTS, SEQUESTERING | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-09-04 | — | — | US | disclosed |
| WO-1989005828-A1 | COMPOUNDS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-06-29 | — | — | WO | disclosed |
| EP-0322209-A1 | Compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-06-28 | — | — | EP | disclosed |
| US-4090024-A | Process for the production of skatylhydantoin | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | ALDH1A1 1320/4885CES2 158/4885CES1 303/4885 |
| US-20230302091-A1 | Combination Therapy with Controlled-Release CNP Agonists | CNP, NPR1, NGF | ALDH1A1 3630/4885CES2 859/4885CES1 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.